You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for SGI-1776

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for SGI-1776?

SGI-1776 is an investigational drug.

There have been 27 clinical trials for SGI-1776. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2017.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Astex Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are two US patents protecting this investigational drug and sixteen international patents.

Recent Clinical Trials for SGI-1776
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaNational Cancer Institute (NCI)Phase 2
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal CancerAstex PharmaceuticalsPhase 1/Phase 2
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal CancerBristol-Myers SquibbPhase 1/Phase 2

See all SGI-1776 clinical trials

Clinical Trial Summary for SGI-1776

Top disease conditions for SGI-1776
Top clinical trial sponsors for SGI-1776

See all SGI-1776 clinical trials

US Patents for SGI-1776

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SGI-1776   Start Trial Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors SuperGen, Inc. (Dublin, CA)   Start Trial
SGI-1776   Start Trial Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors Tolero Pharmaceuticals, Inc. (Salt Lake City, UT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SGI-1776

Drugname Country Document Number Estimated Expiration Related US Patent
SGI-1776 Australia 2007316417 2026-11-06   Start Trial
SGI-1776 Brazil PI0718029 2026-11-06   Start Trial
SGI-1776 Canada 2667487 2026-11-06   Start Trial
SGI-1776 China 101600718 2026-11-06   Start Trial
SGI-1776 European Patent Office 2086979 2026-11-06   Start Trial
SGI-1776 Japan 2010509242 2026-11-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.